My NCBISign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination
  • Your browser version may not work well with NCBI's Web applications. More information here...

Results: 1 to 20 of 413

1.

Can the state of cancer chemotherapy resistance be reverted by epigenetic therapy?

Perez-Plasencia C, Duenas-Gonzalez A.

Mol Cancer. 2006 Jul 10;5:27.PMID: 16831224 [PubMed - indexed for MEDLINE]Related articlesFree article

2.

Epigenetics in cancer: targeting chromatin modifications.

Ellis L, Atadja PW, Johnstone RW.

Mol Cancer Ther. 2009 Jun;8(6):1409-20. Epub 2009 Jun 9. Review.PMID: 19509247 [PubMed - indexed for MEDLINE]Related articles

3.

Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.

Sigalotti L, Fratta E, Coral S, Cortini E, Covre A, Nicolay HJ, Anzalone L, Pezzani L, Di Giacomo AM, Fonsatti E, Colizzi F, Altomonte M, Calabrò L, Maio M.

J Cell Physiol. 2007 Aug;212(2):330-44. Review.PMID: 17458893 [PubMed - indexed for MEDLINE]Related articles

4.

Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets.

Chekhun VF, Lukyanova NY, Kovalchuk O, Tryndyak VP, Pogribny IP.

Mol Cancer Ther. 2007 Mar;6(3):1089-98.PMID: 17363502 [PubMed - indexed for MEDLINE]Related articlesFree article

5.

Molecular targets for epigenetic therapy of cancer.

Humeniuk R, Mishra PJ, Bertino JR, Banerjee D.

Curr Pharm Biotechnol. 2009 Feb;10(2):161-5. Review.PMID: 19199948 [PubMed - indexed for MEDLINE]Related articles

6.

Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker.

Teodoridis JM, Strathdee G, Brown R.

Drug Resist Updat. 2004 Aug-Oct;7(4-5):267-78. Review.PMID: 15533764 [PubMed - indexed for MEDLINE]Related articles

7.

DNA methylation and histone modifications in patients with cancer: potential prognostic and therapeutic targets.

Herranz M, Esteller M.

Methods Mol Biol. 2007;361:25-62. Review.PMID: 17172706 [PubMed - indexed for MEDLINE]Related articles

8.

The clinical application of targeting cancer through histone acetylation and hypomethylation.

Gilbert J, Gore SD, Herman JG, Carducci MA.

Clin Cancer Res. 2004 Jul 15;10(14):4589-96. Review.PMID: 15269129 [PubMed - indexed for MEDLINE]Related articlesFree article

9.

New therapeutic targets in cancer: the epigenetic connection.

Herranz M, Esteller M.

Clin Transl Oncol. 2006 Apr;8(4):242-9. Review.PMID: 16648099 [PubMed - indexed for MEDLINE]Related articles

10.

Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs.

Baker EK, Johnstone RW, Zalcberg JR, El-Osta A.

Oncogene. 2005 Dec 1;24(54):8061-75.PMID: 16091741 [PubMed - indexed for MEDLINE]Related articles

11.

DNA methylation: an epigenetic pathway to cancer and a promising target for anticancer therapy.

Worm J, Guldberg P.

J Oral Pathol Med. 2002 Sep;31(8):443-9. Review.PMID: 12220350 [PubMed - indexed for MEDLINE]Related articles

12.

Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.

Abbosh PH, Montgomery JS, Starkey JA, Novotny M, Zuhowski EG, Egorin MJ, Moseman AP, Golas A, Brannon KM, Balch C, Huang TH, Nephew KP.

Cancer Res. 2006 Jun 1;66(11):5582-91.PMID: 16740693 [PubMed - indexed for MEDLINE]Related articlesFree article

13.

Targeting DNA methylation in cancer.

Szyf M.

Bull Cancer. 2006 Sep 1;93(9):961-72.PMID: 16980240 [PubMed - indexed for MEDLINE]Related articlesFree article

14.

Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.

Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T, Huang Z, Bentley RC, Mori S, Fujii S, Marks JR, Berchuck A, Murphy SK.

Oncogene. 2009 Jan 15;28(2):209-18. Epub 2008 Oct 6.PMID: 18836486 [PubMed - indexed for MEDLINE]Related articles

15.

[Chromatin epigenetic modifications in cancer generation]

Arenas-Huertero F, Recillas-Targa F.

Gac Med Mex. 2002 Nov-Dec;138(6):547-55. Review. Spanish. PMID: 12532619 [PubMed - indexed for MEDLINE]Related articles

16.

Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes.

Calcagno AM, Fostel JM, To KK, Salcido CD, Martin SE, Chewning KJ, Wu CP, Varticovski L, Bates SE, Caplen NJ, Ambudkar SV.

Br J Cancer. 2008 May 6;98(9):1515-24. Epub 2008 Apr 1.PMID: 18382425 [PubMed - indexed for MEDLINE]Related articlesFree article

17.

Differential modulation of nuclear texture, histone acetylation, and MDR1 gene expression in human drug-sensitive and -resistant OV1 cell lines.

Yatouji S, El-Khoury V, Trentesaux C, Trussardi-Regnier A, Benabid R, Bontems F, Dufer J.

Int J Oncol. 2007 Apr;30(4):1003-9.PMID: 17332941 [PubMed - indexed for MEDLINE]Related articles

18.

Epigenetic tête-à-tête: the bilateral relationship between chromatin modifications and DNA methylation.

D'Alessio AC, Szyf M.

Biochem Cell Biol. 2006 Aug;84(4):463-76. Review.PMID: 16936820 [PubMed - indexed for MEDLINE]Related articles

19.

Epigenetic gene regulation in cancer.

Ballestar E, Esteller M.

Adv Genet. 2008;61:247-67. Review.PMID: 18282509 [PubMed - indexed for MEDLINE]Related articles

20.

Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.

Zhong S, Fields CR, Su N, Pan YX, Robertson KD.

Oncogene. 2007 Apr 19;26(18):2621-34. Epub 2006 Oct 9.PMID: 17043644 [PubMed - indexed for MEDLINE]Related articles

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Filter your results:

Find related data

Recent activity

You are here: NCBI > Literature > PubMed
Write to the Help Desk